Ordering Recommendation

First- or second-tier screening test for the common fetal aneuploidy disorders: trisomy 13, trisomy 18, trisomy 21 (Down syndrome), Turner syndrome, sex chromosome aneuploidies (XXX, XXY, XYY), and triploidy; as well as microdeletions causing 22q11.2 deletion (DiGeorge or velocardiofacial [VCFS] syndrome), 1p36 deletion, Angelman, Prader-Willi, and cri-du-chat (5p-) syndromes. Testing may be offered to pregnant women from 9 weeks 0 days gestation to term. Test is not recommended for women who are carrying more than one fetus or have a known twin demise, patients who have used an egg donor, surrogates who have not used their own egg, or women who have had an allogenic bone marrow transplant.




Targeted Sequencing with SNPs




12-14 days

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation

Whole blood in Cell-Free DNA BCT Tube. All specimens must be collected using the NIPT ANEU kit (ARUP Supply #50223) available online through eSupply or contacting ARUP Client Services at (800) 522-2787.
Required Specimen: Maternal specimens must be collected in 2 Cell-Free DNA BCT tubes.

Specimen Preparation

Transport 20 mL maternal blood in Cell-Free DNA BCT Tube (ARUP Supply #50223) available online through eSupply or contacting ARUP Client Services at (800) 522-2787. (Min: 16 mL)

Storage/Transport Temperature

Room temperature.

Unacceptable Conditions

Patient History for Non-Invasive Prenatal Testing (NIPT) form required.


Ambient: 5 days; Refrigerated: Unacceptable; Frozen: Unacceptable

Reference Interval

By report

Interpretive Data

Refer to report.

Compliance Category

Not Applicable


Testing utilizes a single-nucleotide polymorphism (SNP)/informatics-based approach to detect fetal copy number for the five chromosomes responsible for the majority of live-birth aneuploidies (chromosomes 13, 18, 21, X, Y, and triploidy) and certain specific microdeletion syndromes (see current list of microdeletion syndromes listed under "Ordering Recommendations"). This is a screening test to help identify fetuses at risk for Down syndrome, trisomy 18, trisomy 13 and Turner syndrome, as well as fetuses affected with the specified microdeletion syndromes listed. This test should not be considered diagnostic. All positive results should be confirmed by amniocentesis or CVS.

Hotline History


CPT Codes

81420; 81422


Component Test Code* Component Chart Name LOINC
2008381 Trisomy 21 73966-4
2008382 Trisomy 18 73825-2
2008383 Trisomy 13 73824-5
2008386 Monosomy X 73821-1
2008430 Fetal Fraction
2008431 Report Fetal Sex? 8251-1
2008830 Triploidy/Vanishing Twin
2009259 Result Summary 48767-8
2009260 Gestational Age at draw (Weeks) 49051-6
2010002 Maternal Weight (Pounds) 8338-6
2010003 Gestational Age at draw (Days) 49052-4
2010004 Fetal Sex 11882-8
2010354 22q11.2 deletion syndrome
2010472 Prader-Willi syndrome 44617-9
2010473 Cri-du-chat syndrome 73751-0
2010474 Angelman syndrome 48024-4
2010475 del 1p36 syndrome
2010646 EER Fetal Aneuploidy w/Microdeletions 11502-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.


  • 45X
  • cell-free
  • cellfree
  • cffDNA
  • edward syndrome
  • Natera
  • NIPD
  • Panorama
  • patau syndrome
  • T13
  • T18
  • trisomy 21
Non-Invasive Prenatal Testing for Fetal Aneuploidy with Microdeletions